Abstract Background: Different molecular forms of urinary neutrophil gelatinase-associated lipocalin (NGAL) have recently been discovered. We aimed to explore the nature, source and discriminatory value of urinary NGAL in intensive care unit (ICU) patients. Methods: We simultaneously measured plasma NGAL (pNGAL), urinary NGAL (uNGAL), and estimated monomeric and homodimeric uNGAL contribution using Western blotting-validated enzyme-linked immunosorbent assays [uNGAL E1 and uNGAL E2 ] and their calculated ratio in 102 patients with the systemic inflammatory response syndrome and oliguria, and/or a creatinine rise of [25 lmol/L.
Measurements and main results:
Bland-Altman analysis demonstrated that, despite correlating well (r = 0.988), uNGAL and uNGAL E1 were clinically distinct, lacking both accuracy and precision (bias: 266.23; 95 % CI 82.03-450.44 ng/mg creatinine; limits of agreement: -1,573.86 to 2,106.32 ng/mg creatinine). At best, urinary forms of NGAL are fair (area under the receiver operating characteristic [AUROC] B0.799) predictors of renal or patient outcome; most perform significantly worse. The 44 patients with a primarily monomeric source of uNGAL had higher pNGAL (118.5 ng/ml vs. 72.5 ng/ml; p \ 0.001), remaining significant following Bonferroni correction. Conclusions: uNGAL is not a useful predictor of outcome in this ICU population. uNGAL patterns may predict distinct clinical phenotypes. The nature and source of uNGAL are complex and challenge the utility of NGAL as a uniform biomarker.
Introduction
Neutrophil gelatinase-associated lipocalin/human neutrophil lipocalin (NGAL/HNL) is a potentially useful biomarker for acute kidney injury (AKI) [1] [2] [3] [4] , and proprietary assays are now available [5] [6] [7] [8] [9] . NGAL was first identified in specific granules of human neutrophils [10] , but has subsequently been found in a variety of cells [11, 12] . Its production is upregulated by oxidative stress, malignancy, infection, ischaemia and inflammation [1, 11, [13] [14] [15] [16] .
More recently, different molecular forms of NGAL have been identified. Neutrophils produce a unique 45-kD homodimer. In contrast, renal tubular epithelial cells do not produce the homodimer; instead they produce a 135-kD heterodimer covalently conjugated with gelatinase. Both cell types also produce a 25-kD monomer ( Fig. 1) . Renal tubular epithelial cells are believed to the primary source of the monomer in the urine [17, 18] .
Most plasma NGAL (pNGAL) appears to come from circulating neutrophils. NGAL measured in the urine could be composed, in part, of NGAL secreted by renal tubular cells and/or local neutrophil release, as well as filtered pNGAL. Unfortunately, commercially available immunoassays appear to measure NGAL utilizing different monoclonal and polyclonal antibody preparations [7] [8] [9] [19] [20] [21] . These have differential performance in the estimation of NGAL [5] and different epitope affinity [22] . These characteristics make the identification of the nature of measured NGAL problematic.
Western blotting has recently demonstrated that the urinary ratio of two different enzyme-linked immunosorbent assays (ELISAs) [ELISA-1 and ELISA-2] can identify the most likely source of NGAL measured in the urine. Similar to commercially available assays, ELISA-1 measures monomeric, homodimeric and heterodimeric urinary NGAL (uNGAL). ELISA-2 measures homodimeric uNGAL (Fig. 1) . In patients with a demonstrated uNGAL ELISA-1:ELISA-2 ratio [50, Western blotting confirmed that the measured uNGAL is monomeric in nature (area under the receiver operating characteristic [AUROC] of 0.92) [23] . In patients with a ratio of \50, the major contributor to uNGAL is likely to be the homodimeric form [23] . These assays and their ratio can help determine the likely source of uNGAL.
Accordingly, we conducted a prospective observational study targeting those critically ill patients most at risk of developing AKI in whom a predictive test offering biological insight into the source of NGAL and its relationship to subsequent AKI may be of greatest utility. Fig. 1 A urine sample may consist of a mixture of the three identified forms of NGAL: monomeric, homodimeric and heterodimeric. Different assays measure different forms and different proportions of the total quantity of each form. Western blotting and an ELISA-1:ELISA-2 ratio allow the identification of the source of the majority of the NGAL in the sample (adapted from [17, 22, 23] ). AUROC area under the receiver operating characteristic, ELISA enzyme-linked immunosorbent assay, NGAL neutrophil gelatinase-associated lipocalin, UTI urinary tract infection We hypothesised that (i) NGAL would be detectable in the urine and plasma of such patients using commercial assays and the research ELISAs; (ii) patients with a uNGAL ELISA-1:ELISA-2 ratio [50 would be at greater risk of AKI; and (iii) that there would be a distinct clinical phenotype in patients with an ELISA-1:ELISA-2 ratio [50.
Materials and methods

Study design
We conducted a prospective observational study of critically ill patients at risk of AKI. The Human Research Ethics Committee at the Austin Hospital, Melbourne, VIC, Australia, approved the study prior to commencement with waiver for consent (Human Ethics Research Committee [HREC] approval number H2011/04219).
Between 1 September 2010 and 17 November 2010, we enrolled all patients within 48 h of intensive care unit (ICU) admission who met the inclusion criteria. In these patients, we simultaneously used commercial assays to measure pNGAL and uNGAL, and research assays ELISA-1 (measuring all forms of NGAL) and ELISA-2 (relatively specific to homodimeric NGAL) to identify the likely source of uNGAL.
Inclusion criteria were age [18 years, the presence of the systemic inflammatory response syndrome (SIRS) and the presence of oliguria, or a 25 lmol/L increase from baseline in their serum creatinine, or both. SIRS was defined according to consensus guidelines [24] . Oliguria was defined as a urine output of \0.5 mL/kg/h for 2 or more consecutive hours. Baseline creatinine was defined as the lowest creatinine measured in the 6 months preceding ICU admission. All creatinine measurements were converted into estimations of glomerular filtration rate (GFR) using the modification of diet in renal disease (MDRD) calculation; in the absence of true baseline creatinine in patients with no history of renal dysfunction, a GFR of 75 mL/min/1.73 m 2 was assigned, as previously described [25] . AKI was defined according to risk, injury, failure, loss, end stage (RIFLE) criteria [26] . Diagnoses and co-morbid illnesses were as defined according to the acute physiology and chronic health evaluation version III (APACHE III) system [27] .
Study protocol
Patients were identified by daily surveillance. We collected clinical, demographic, physiologic and laboratory data, and outcomes. Urine and blood for NGAL analysis were obtained for each patient on enrolment only. Serum creatinine, as measured by point-of-care testing [28] at study inclusion, was also documented.
Urine samples were stored at -70°C for batched analysis. uNGAL was measured by a chemiluminescent microparticle assay using the ARCHITECT platform (Abbott Diagnostics Inc., Abbott Park, IL, USA), as previously described [9] . uNGAL measurements were expressed as ng/mg creatinine, to standardize and correct for changes in urine concentration [3] .
ELISA-1 was performed utilising monoclonal antibody clones m763/764, while ELISA-2 utilised monoclonal antibody clones m763/765, as previously described [17, 22, 23] . ELISA-1:ELISA-2 ratios were calculated as previously described [23] .
Blood samples for pNGAL were collected in EDTA anti-coagulated tubes and analysed immediately using the Triage NGAL Test (Alere, San Diego, CA, USA), a pointof-care, fluorescence immunoassay for quantitative measurement of pNGAL, as previously described [8] .
Statistical analysis
Statistical analyses were performed with SPSS version 20 (IBM, North Castle, NY, USA). Non-normally distributed continuous data are reported as medians with either interquartile (IQR) or total range and compared using the Mann-Whitney U test, Kruskal-Wallis test or Friedman test where appropriate. The Bonferroni correction was used to account for multiple testing. Categorical data are reported as proportions and compared using the Fisher exact test. The relationship between variables was assessed using Spearman's rank correlation co-efficient. We used the following values to describe the strength of correlation: [0.9 very strong, 0.68-0.9 strong, 0.3-0.67 moderate, \0.3 weak [29] . The Bland-Altman technique was used to compare methods [30] [31] [32] . The individual measures and the ratio of the different forms of NGAL were assessed for their ability to predict AKI, renal replacement therapy (RRT) initiation and mortality using the AUROC curve. We used the following values to describe AUROCs: 0.90-1.0 excellent, 0.80-0.89 good, 0.70-0.79 fair, 0.60-0.69 poor and 0.50-0.59 no useful performance [33] . A p-value of \0.05 was considered statistically significant.
Results
We studied 102 patients with a median age of 66 (53-75) years and median APACHE III score of 63.5 (46-78); 73.53 % of patients were mechanically ventilated and 6.87 % eventually required continuous renal replacement therapy (CRRT) [ Table 1 ]. Baseline and worst creatinine and GFR values are presented in Table 1 . Of note, 54 (52.95 %) of patients had risk class of RIFLE classification (RIFLE-R) or greater AKI on study admission ( Table 1 ).
The median time to enrolment from ICU admission was 0.69 (0.49-1.27) days. At enrolment, median pNGAL was 97 (60-260.25) ng/mL. Median uNGAL was 82.09 (27.18-413.52) ng/mg creatinine. The median uNGAL reported by ELISA-1 (uNGAL E1 ) and the median uNGAL reported by ELISA-2 (uNGAL E2 ) are presented in Table 1 . Overall, 44 (43.14 %) of the 102 patients had a uNGAL E1 :uNGAL E2 ratio [50.
Correlations
There was a moderate correlation between pNGAL and uNGAL E1 , and between pNGAL and uNGAL; there was no significant correlation between pNGAL and uNGAL E2 . There was a very strong correlation between (Fig. 2) .
Bland-Altman analysis was repeated after natural logarithmic transformation of the variables (see Fig. E2 , ESM) [30, 32] . While this removed the systematic bias, 95 % of the values of uNGAL were still within 0.86-2.8 times the value of uNGAL E1 .
Acute kidney injury, renal replacement therapy and death Overall, 72 of the 102 patients developed AKI compared with baseline. Of these, 7 (6.87 %) received RRT (Table 1) . No measure or derivation of NGAL was a useful predictor of hospital or intensive care mortality. NGAL measured by ELISA-2 was a poor predictor of any Table 2 ). The uNGAL E1 :uNGAL E2 ratio was not a useful predictor of outcome. pNGAL demonstrated good ability to predict failure class of RIFLE classification (RIFLE-F) AKI, and was a fair predictor of the need for CRRT.
No urinary measure of NGAL was a useful predictor of the development of AKI (Table 2 ). Both uNGAL and uNGAL E1 were fair predictors of the development of RIFLE-F AKI, but did not predict the need for CRRT, with 95 % CIs of the AUROC inclusive of 0.5.
Patient stratification
Overall, 44 (43.14 %) of the 102 patients had uNGA-L E1 :uNGAL E2 ratios [50. These patients trended towards increased rates of diagnoses of sepsis or acute liver failure, but lower rates of admission following an emergency call (Table 3) . They trended towards higher baseline creatinine and lower minimum MDRD-derived GFR. More of these patients developed injury class of RIFLE classification (RIFLE-I) AKI. The two groups demonstrated clear NGAL and uNGAL E1 :uNGAL E2 ratio separation (Table 3) . Only the differences in NGAL measurement remained significant after Bonferroni correction. When stratified for the presence of AKI on study recruitment, patient groups had the expected differences in serum creatinine, GFR and the presence of AKI, as well as a significant difference in pNGAL (median pNGAL 64 ng/mL in patients without AKI, and 143.5 ng/ mL in those with; p \ 0.001). These differences retained significance after Bonferroni correction (Table E3 ,ESM).
Discussion
Statement of key findings
We assessed the relationships between pNGAL, uNGAL, uNGAL E1 and uNGAL E2 , whose ratio can determine the likely nature and source of uNGAL. We investigated their ability to predict the development of AKI, the need for CRRT and ICU and in-hospital mortality in undifferentiated critically ill admissions to the ICU, and found a lack of clinically acceptable performance. No urinary measure of NGAL was found, in this patient population, to be suitable for clinical use in a pragmatic fashion in the ICU. We found that plasma and urinary measurements of NGAL had limited correlation. We further found a strong relationship between uNGAL and uNGAL E1 , consistent with the observation that both assays measure all of the urinary forms of NGAL. Despite this strong relationship, the limits of agreement were too wide to permit interchange of measurement clinically.
In this population, both uNGAL and uNGAL E1 were poorly predictive of AKI, the need for CRRT and mortality. In contrast, pNGAL, which is thought to be primarily homodimeric neutrophil NGAL [23] , showed fair discrimination for predicting CRRT, and good discrimination for RIFLE-F AKI. However, uNGAL measured by uNGAL E2 had no significant correlation with pNGAL, implying that it is unlikely to represent a renally filtered pNGAL.
Finally, the ratios of pNGAL to urinary measures, and the uNGAL E1 :uNGAL E2 ratio, were not useful predictors of any outcome, although patients with uNGAL E1 :uNGAL E2 [50 (monomeric NGAL of renal origin) were more likely to have septic AKI, liver failure and elevated pNGAL levels.
Relationship with previous studies NGAL has been reported to be a good-to-excellent predictor of renal outcomes in highly specific groups of patients [1, 3, 9, [33] [34] [35] [36] [37] [38] , confirmed on meta-analysis [39] . However, the actual nature of the NGAL being measured with commercial assays remains unclear [5] , particularly given the presence of different molecular forms of NGAL whose proportions seem to change with time [17, 22, 23] . In such ICU patients, uNGAL has demonstrated variable ability to predict AKI [40] [41] [42] [43] [44] [45] [46] [47] and CRRT [40, 41, 43, 47] . NGAL was a poor indicator of subsequent hospital mortality [40, 41, 43] , with only a single Japanese study finding it useful only at a non-standardized point of follow-up [42] . In contrast, pNGAL poorly predicts mortality [40, 41, 48] , but is a fair-to-excellent predictor of AKI [40, 41, 44, 45, 48, 49] and a fair-to-good predictor of CRRT use [40, 41, 48, 49] . In an undifferentiated ICU population, pNGAL and uNGAL demonstrated similarly poor predictive value [47] .
The plasma:urinary ratios of NGAL and the temporal changes in ratio in septic and non-septic patients have been described previously, although with no comment on All values are presented as median (IQR) or as absolute number (%) AKI acute kidney injury, CRRT chronic renal replacement therapy, ELISA enzyme-linked immunosorbent assay, GFR glomerular filtration rate, ICU intensive care unit, IQR interquartile range, NGAL neutrophil gelatinase-associated lipocalin, pNGAL commercial plasma/serum NGAL, POC point of care, RIFLE-R risk class of RIFLE classification, RIFLE-I injury class of RIFLE classification, RIFLE-F failure class of RIFLE classification, uNGAL commercial urinary NGAL, uNGAL E1 NGAL as detected by ELISA-1, uNGAL E2 NGAL as detected by ELISA-2; * indicates significance retained following Bonferroni correction for multiple univariate analyses predictive ability [40] . In an undifferentiated ICU population, pNGAL and uNGAL demonstrated similarly poor predictive value [47] . Despite the existence of the RIFLE criteria [26] , the definitions of AKI differ throughout the literature, making direct comparison even more problematic [50] . It is also difficult to compare studies using different commercial NGAL assays; the lack of agreement between such assays has been clearly demonstrated [5] . Different commercial assays utilise different mono-and polyclonal antibody combinations, have different epitope specificities, and detect different proportions of the various molecular forms of uNGAL [5, 17, 22] . In addition, different calibrators are used by different companies, adding a systematic bias to any direct comparisons [19, 22, 51] .
Study significance
Our study is the first to investigate the predictive value of three different types of uNGAL measurement simultaneously in ICU patients at risk of AKI; the first to directly compare the measurement of uNGAL by commercial assay and by techniques with relative specificity for homodimeric NGAL; and the first to look at plasma:urinary ratios of the different urinary forms and to demonstrate biochemical differences and a trend towards differences in clinical phenotype in critically ill patients stratified by uNGAL E1 :uNGAL E2 ratio. Finally, it is the first to assess the clinical utility of these laboratory techniques in a population of patients with a phenotype that justifies a high index of suspicion of likely subsequent AKI. It is in this very population that a test which can predict which patients will go on to develop AKI requiring CRRT and/or achieve successful independent resolution of their AKI would appear most useful.
Our findings fully challenge the current simplistic views of NGAL biology.
First, homodimeric uNGAL E2 is a uniformly poor predictor of patient-centred outcomes in this population. Given the dissociation between pNGAL and uNGAL E2 , and given that pNGAL is mostly neutrophil-derived homodimeric NGAL, uNGAL E2 is unlikely to come from filtered pNGAL. Thus, its release may not be as indicative of tubular stress as the release of the monomeric form. This notion is reinforced by the greater median pNGAL and smaller median uNGAL E2 results reported in patients with uNGAL E1 :uNGAL E2 ratios [50.
Second, commercial uNGAL assays measure mostly monomeric NGAL, but also detect a variable amount of heterodimeric and homodimeric NGAL too. Therefore, the quantification of uNGAL remains challenging as uNGAL E1 and uNGAL cannot be used interchangeably.
Third, patients can be stratified by uNGA-L E1 :uNGAL E2 ratio with significant differences in biochemical and clinical characteristics. Patient with ratios [50 have significantly higher pNGAL measurements, and a higher incidence of sepsis and acute liver failure. Neutrophil activation in sepsis [7] and liver disease could account for the high levels of pNGAL demonstrated in these patients.
Finally, our findings imply that widespread use of NGAL in ICU patients at potential risk of AKI is premature and should wait for a better understanding of the biology of this biomarker.
Limitations of this study
This is a single-centre study and its findings may not apply to other centres. However, our ICU has all the typical features of an academic ICU within a tertiary hospital of a developed country, suggesting a degree of external validity. We made no correction for hypotension, inotropes, the fluid loading or the use of furosemide. Yet, to be useful in ICU patients, modern biomarkers must be able to perform well in a heterogeneous population irrespective of such confounders. The use of changes in serum creatinine to judge the value of biomarkers such as NGAL has been called into question [3, 52, 53] . This is why we also sought to relate NGAL values to the need for CRRT or mortality. For both, performance was poor.
We measured NGAL at only a single timepoint, up to 48 h after admission to the ICU. The temporal release profile of the different forms of NGAL is unclear [17, 22, 23] . The most impressive discriminatory abilities of NGAL seem to be when measured within hours of the insult [1, 9, 35, 36, 39] . It is possible that the renal insult in some of these patients occurred after ICU admission. However, the median time to peak creatinine observed was 1.06 days post-ICU admission, making this unlikely. Indeed, the movement of biomarkers from experimental to clinical practice means that they must be robust enough to account for the variability that exists between the onset of critical illness and presentation to intensive care.
By including those patients with a 25 lmol/L increase in serum creatinine we are including a population of patients who may have had an insult 12-24 h previously that had technically resulted in kidney disease improving global outcomes (KDIGO) AKI [54] . Although including such patients may introduce selection bias, given their increased risk of developing AKI and dying in the ICU [55] [56] [57] , these are precisely the patients in whom prediction may be most useful.
The inter-relationship between uNGAL and the different molecular forms of NGAL in the urine remains poorly understood. The relative contribution of renallyfiltered pNGAL to uNGAL levels, or the back-leak of monomeric, renal-specific NGAL released into the plasma by tubular damage, is unclear, as are the temporal relations of release. Heterodimeric NGAL is present in the urine in only very small quantities [23] , is difficult to quantify, and has not been directly measured in this study. The ability of heterodimeric NGAL to predict AKI and outcome remains unknown. In addition, uNGAL E2 appears to only measure a portion of the homodimeric NGAL present in the urine, possibly due to differences in epitope availability between the monomeric and homodimeric forms [23] . Recent studies have begun to examine these relationships [22, 23] , but not yet in sufficient detail to allow conclusions to be drawn in the chaotic and confounding environment of the ICU. It is likely that differential patterns of biomarker release will emerge and therefore require specific assessment [34] .
Conclusions
In a high-risk population, both pNGAL and uNGAL may represent NGAL release from a broad range of cells and have limited predictive value for mortality, the need for CRRT or the development of AKI. Moreover, pNGAL may be of greater value as a biomarker of AKI than uNGAL, or any of the specific urinary forms of NGAL. Finally, differences in patient demographics and biochemical parameters can be demonstrated when uNGAL is primarily monomeric or homodimeric in nature. Despite the increasing availability of commercial assays, this suggests the need for further investigations to define the natural history of the release of the different forms of NGAL in ICU patients with SIRS and early renal dysfunction before NGAL can be used to identify critically ill patients who will develop severe AKI or the need for CRRT.
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